Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

cessful NDA filing and furthering our discussions with potential collaboration partners."

Based upon the discussions with FDA, Palatin intends to finalize the protocols for the pivotal Phase 3 clinical studies and start screening patients later this year.

Quarter Ended March 31, 2013 Financial Results
For the three months ended March 31, 2013, Palatin reported a net loss of $4.0 million, or $(0.04) per basic and diluted share, compared to a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the same period in 2012. 

The decrease in net loss for the quarter ended March 31, 2013, compared to the same period last fiscal year, is attributable to a decrease in operating expenses primarily related to Palatin's Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD. 

Revenue
Palatin did not recognize any revenues for the quarter ended March 31, 2013, compared to $23,996 for the quarter ended March 31, 2012.  Revenue consists of contract revenue under our collaboration agreement with AstraZeneca.

Costs and Expenses
Total operating expenses for the quarter ended March 31, 2013 were $4.0 million compared to $6.1 million for the comparable quarter of 2012.  The decrease in operating expenses for the quarter was primarily due to Palatin's Phase 2B clinical trial with bremelanotide for FSD and secondarily as a result of closing our research laboratory operations in connection with the lease expiration of the laboratory facilities in July 2012.

Cash Position
As of March 31, 2013, Palatin had cash and cash equivalents of $23.5 million, $6.0 million in short term investments and current liabilities of $2.7 million.  Cash and cash equivalents as of June 30, 2012 were $3.8 million with current liabilities of $3.5 million. 

Palatin believes that its existing capital resources will be adequate to fund its currently planned opera
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014 RPS Diagnostics (RPS®) – ... today announces its third annual partnership of the ... Smart About Antibiotics Week from November 17-23. , ... campaign designed to highlight the coordinated efforts of ... and for-profit partners to provide education about the ...
(Date:11/18/2014)... CA (PRWEB) November 17, 2014 Athena Signature ... Salk , Dr. Beverly Emerson, a professor in the Regulatory ... genes. Her most recent discovery points to an “off switch” ... Emerson’s career and how her local research is making a ... present her findings and then join host Cheryl K. Goodman, ...
(Date:11/18/2014)... Ft. Lauderdale, FL (PRWEB) November 18, 2014 ... 12) have announced the launch of PAWSitively Curing ... Awareness Month. This new 501(c) (3) non-profit organization is ... Every dollar donated goes directly to the University ... proud to partner with PAWSitively Curing Cancer as the ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
Breaking Biology Technology:RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... and AMSTERDAM, May 21 ,Agendia, a world leader in ... the University of California San Francisco ,and the ... the American Society of Clinical Oncology Annual Meeting, May ... The study results further underpin the ...
... Beach Marriott Resort and Spa in Waikoloa, Hawaii, has ... the Hydrologix GRS, which transforms their restaurants, brown grease ... trap! Their choice of both a cost-cutting and "green" ... economic times since the innovative GRS drastically reduces the ...
... 20 Keryx Biopharmaceuticals, Inc. (the "Company") (Nasdaq: ... Chief Executive Officer of the Company. It is also anticipated ... at the annual meeting of the board on June 16, ... Directors, stated, "On behalf of the Board, I want to ...
Cached Biology Technology:Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting 2Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting 3Marriott Resort Magically Turns Brown Grease "Green" With The Cost-Cutting Hydrologix GRS 2Marriott Resort Magically Turns Brown Grease "Green" With The Cost-Cutting Hydrologix GRS 3Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer 2Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer 3Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer 4
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
(Date:11/6/2014)... paper from a team of Florida State University biologists ... could adapt to and survive environmental swings such as ... latest issue of the journal The Plant Cell ... DNA and proteins) is organized in a cell and ... are turned on and others are turned off. , ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2
... least death, are the key to reproduction for the orchid Satyrium ... of KwaZulu-Natal shows that the orchid lures flies into its flowers ... the scent of the orchids with that of roadkill is to ... . The orchid S. pumilum is found in sandy, ...
... University have uncovered a new understanding of how male puberty ... with a protein known as SMAD3 and the rate at ... Catherine Itman from the Faculty of Medicine, Nursing and Health ... SMAD3 protein results in faster maturation than the norm, and ...
... of Cincinnati (UC) researchers have determined the structure of ... explain how this "fat packet" protects against cardiovascular diseases, ... led by W. Sean Davidson, PhD, professor in UC,s ... print March 13, 2011, in the journal Nature ...
Cached Biology News:Orchid wears the scent of death 2Monash scientists uncover a new understanding of male puberty 2'Good cholesterol' structure identified, could help explain protective effects 2
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
Cytofix Buffer 100 mls...
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Biology Products: